1. Clinical effectiveness of DREAMS START (Dementia Related Manual for Sleep; Strategies for Relatives) versus usual care for people with dementia and their carers: a single-masked, phase 3, parallel-arm, superiority randomised controlled trial.
- Author
-
Rapaport P, Amador S, Adeleke MO, Barber JA, Banerjee S, Charlesworth G, Clarke C, Espie CA, Gonzalez L, Horsley R, Hunter R, Kyle SD, Manela M, Raczek M, Walker Z, Webster L, Yuan H, and Livingston G
- Subjects
- Humans, Female, Male, Aged, Aged, 80 and over, Sleep Wake Disorders therapy, Sleep Wake Disorders psychology, Single-Blind Method, Treatment Outcome, Dementia therapy, Caregivers psychology, Caregivers education
- Abstract
Background: Sleep disturbances are common and distressing for people with dementia and their families. Non-pharmacological interventions should be first-line management, avoiding harmful pharmacological side-effects, but there is none with known effectiveness. We aimed to establish whether DREAMS START, a multicomponent intervention, reduced sleep disturbance in people with dementia living at home compared with usual care., Methods: We conducted a phase 3, two-arm, multicentre, parallel-arm, superiority randomised controlled trial with masked outcome assessment, recruiting dyads of people with dementia and sleep disturbance and family carers from community settings. Randomisation to the DREAMS START intervention (plus usual treatment) or usual treatment was conducted at dyadic level, blocked, and stratified by site, with a web-based system assigning allocation. DREAMS START is a six-session, manualised intervention delivered face to face or remotely by non-clinically trained graduates over an approximately 3-month period. The primary outcome was sleep disturbance measured by the Sleep Disorders Inventory (SDI) at 8 months. Analyses were on the intention-to-treat population. This trial is registered with ISRCTN 13072268., Findings: Between Feb 24, 2021, and March 5, 2023, 377 dyads were randomly assigned (1:1), 189 to usual treatment and 188 to intervention. The mean age of participants with dementia was 79·4 years (SD 9·0), and 206 (55%) were women. The mean SDI score at 8 months was lower in the intervention group compared with the usual treatment group (15·16 [SD 12·77], n=159, vs 20·34 [16·67], n=163]; adjusted difference in means -4·70 [95% CI -7·65 to -1·74], p=0·002). 17 (9%) people with dementia in the intervention group and 17 (9%) in the control group died during the trial; the deaths were unrelated to the intervention., Interpretation: To our knowledge, DREAMS START is the first multicomponent intervention to improve the sleep of people living at home with dementia more than usual clinical care. It had sustained effectiveness beyond intervention delivery. The intervention's delivery by non-clinically trained graduates increases the potential for implementation within health services, adding to usual clinical care., Funding: National Institute for Health and Care Research Health Technology Assessment., Competing Interests: Declaration of interests PR reports grants from the National Institute for Health and Care Research (NIHR) Academy (NIHR300844) and NIHR Programme Grants for Applied Research (PGfAR; NIHR200120 and NIHR203670); and support from the University College London (UCL) Hospitals NIHR Biomedical Research Centre. GL reports support from the UCL Hospitals NIHR Biomedical Research Centre, North Thames NIHR Applied Research Collaboration (ID1861414), and as an NIHR Senior Investigator (NIHR201321); and grants from NIHR PGfAR (NIHR202345 and NIHR203670), the Alzheimer’s Association and Brain Canada (ARCOM-22–875327), the Norwegian Research Council (ES637280), and Wellcome (UNS114095 and 00222932/Z/21/Z). JAB reports support from the UCL Hospitals NIHR Biomedical Research Centre. SB reports grants from NIHR, the Canadian Institutes of Health Research, the Economic and Social Research Council, Health Education England, the Engineering and Physical Sciences Research Council, Alzheimer’s Society, and the Alzheimer’s Association; personal fees from Lilly, Boehringer Ingelheim, Axovant, Lundbeck, and Nutricia; non-financial support from Lilly; honoraria for lectures and talks from the Hamad Medical Service; being a trustee of Alzheimer’s Society; and non-executive directorship at the Somerset NHS Foundation Trust. CAE reports grants from NIHR Health Technology Assessment (HTA; 12/87/61 and 16/84/01); NIHR Efficacy and Mechanism Evaluation (NIHR131789); NIHR Oxford Health Biomedical Research Centre (NIHR203316) , and Wellcome. SDK reports grants from NIHR Oxford Health Biomedical Research Centre (NIHR203316), NIHR HTA (12/87/61 and 16/84/01), NIHR Efficacy and Mechanism Evaluation (NIHR131789), NIHR PGfAR (NIHR203667), and Wellcome (226784/Z/22/Z and 227093/Z/23/Z); stock or stock options from Big Health; being Deputy Editor of the Journal of Sleep Research; being on the editorial board of Sleep Medicine Reviews; and non-financial support from Big Health in the form of no-cost access to the digital sleep improvement programme Sleepio, for use in clinical research. MR reports a grant from NIHR Applied Research Collaboration Kent, Surrey and Sussex and Alzheimer’s Research UK; and an honorarium for a presentation on Lewy body dementias for GE HealthCare. HY reports a studentship from Novo Nordisk. All other authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF